JP7523892B2 - Skin preparations - Google Patents

Description

The present invention relates to a skin preparation for external use.

It has been known to blend spherical polymer powders such as crosslinked silicone powder (see Patent Document 1), nylon powder (see Patent Document 2), and acrylic powder (see Patent Document 3) into cosmetics in order to improve the feel and smoothness during application as well as the pore blurring effect and bare skin feel and transparency.

Japanese Patent Application Publication No. 1-165509 Japanese Patent Application Publication No. 7-300410 Special Publication No. 10-502389 Patent No. 3998519

However, when these spherical polymer powders are incorporated into external skin preparations, there are problems such as the absorption of sebum over time, causing the skin to dry out.
Therefore, an object of the present invention is to provide an external preparation for the skin which has good cosmetic durability and a long-lasting moisturizing effect.

As a result of intensive research into such problems, the present inventors have completed the present invention.
A skin topical preparation containing (A) and (B) is provided.
(A): One or more selected from boron nitride, barium sulfate, acylamino acid powder, glittering powder, spherical silica, spherical calcium carbonate, spherical cellulose, spherical starch, spherical modified starch, and spherical silk; (B): Spherical glass beads having an average particle size of 0.1 to 20 μm.

The topical skin preparation of the present invention has the effect of maintaining the smooth feel of spherical powder while providing sustained moisturizing effects.

The following describes in detail the embodiments of the present invention. However, the present invention is not limited to the following embodiments.

The boron nitride can be any type that is commonly used in topical skin preparations, without any particular limitations. The boron nitride may be in the form of a hexagonal crystal, a wurtzite structure, a cubic crystal, a rhombohedral crystal, a turbostratic structure, or the like, with the hexagonal crystal being preferred from the standpoint of ease of use.

From the viewpoint of good adhesion when applied to the skin, boron nitride preferably has an average particle size of 3 to 40 μm, more preferably 5 to 30 μm, and even more preferably 12 to 20 μm. The shape is preferably plate-like.

Commercially available boron nitrides include SHP-3, SHP-4, SHP-5, SHP-6, and SHP-7 (all manufactured by Mizushima Ferroalloy Co., Ltd.), BORON NITRADE POWDER SA08 (manufactured by NATIONAL NITRADE TECH Co., Ltd.), Boroneige SF-3, Boroneige SF-9, and Boroneige SF-12 (all manufactured by Merck & Co., Ltd.), etc.

When boron nitride is included, the content is preferably 0.1% by mass or more, more preferably 0.2% by mass or more, and even more preferably 0.5% by mass or more, preferably 35% by mass or less, more preferably 25% by mass or less, and even more preferably 10% by mass or less, based on the total amount of the topical skin preparation, from the viewpoints of good adhesion, good spreadability, and ease of spreading when applied to the skin, and suppression of stickiness after application.

Barium sulfate can be used without any particular restrictions as long as it is used in ordinary skin external preparations. Barium sulfate may be in the form of a plate, butterfly, amorphous, or spherical shape. Barium sulfate that has been surface-treated with silicone, alkyl, alkylsilane, metal soap, water-soluble polymer, amino acid, N-acylamino acid, lecithin, organic titanate, polyol, acrylic resin, methacrylic resin, or urethane resin can also be used. Spherical barium sulfate will be described separately. Commercially available plate barium sulfate products include plate barium sulfate H, plate barium sulfate HG, and plate barium sulfate HL (all manufactured by Sakai Chemical Industry Co., Ltd.).

When barium sulfate is included, the content is preferably 0.1% by mass or more, more preferably 0.2% by mass or more, even more preferably 0.5% by mass or more, preferably 35% by mass or less, more preferably 25% by mass or less, and even more preferably 10% by mass or less, based on the total amount of the topical skin preparation.

The acyl amino acid powder can be any one that is used in ordinary skin external preparations, without any particular limitations. Specific examples of acyl amino acid powder include acyl lysines such as lauroyl lysine, palmitoyl lysine, and caproyl lysine; acyl ornithines such as stearoyl ornithine; acyl arginines such as lauroyl arginine; and acyl histidines such as cocoyl histidine. Commercially available products that can be used include Amihope LL (manufactured by Ajinomoto Co., Inc.), which is lauroyl lysine.

When acylamino acid powder is added, the content is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, even more preferably 0.3% by mass or more, preferably 15% by mass or less, more preferably 12% by mass or less, and even more preferably 10% by mass or less, based on the total amount of the topical skin preparation.

The glittering powder is not particularly limited as long as it is one that is normally used in topical skin preparations, and examples thereof include body powders such as mica, sericite, synthetic mica, synthetic sericite, aluminum silicate, magnesium silicate, magnesium aluminum silicate, cleaved talc, plate-shaped silicic acid anhydride, plate-shaped aluminum oxide, plate-shaped kaolin, plate-shaped boron nitride, plate-shaped titanium oxide, and plate-shaped cellulose; glittering powders such as titanium mica, bismuth oxychloride, organic pigment-treated titanium mica, titanium dioxide-coated mica, titanium dioxide-coated synthetic phlogopite, titanium dioxide-coated bismuth oxychloride, iron oxide mica titanium, Prussian blue-treated titanium mica, carmine-treated titanium mica, fish scale foil, titanium dioxide-coated glass powder, and resin laminate powders such as polyethylene terephthalate-aluminum-epoxy laminate powder, polyethylene terephthalate-polyolefin laminate film powder, and polyethylene terephthalate-polymethyl methacrylate laminate film powder; and the like, and these may be used alone or in combination of two or more. Among these, glittering powders based on mica, synthetic mica, and glass powder are preferred because they have a good luster. These glittering powders may be surface-treated with one or more of fluorine-based compounds, silicone-based compounds, metal soaps, lecithin, hydrogenated lecithin, collagen, hydrocarbons, higher fatty acids, higher alcohols, esters, waxes, surfactants, amino acids and their derivatives, polyhydric alcohols, etc.

When a glittering powder is included, the content is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and even more preferably 0.3% by mass or more, and is preferably 80% by mass or less, and more preferably 70% by mass or less, based on the total amount of the topical skin preparation.

Spherical silica, spherical calcium carbonate, spherical barium sulfate, spherical cellulose, spherical starch, and spherical modified starch are spherical powders. In addition to true spheres, ellipsoids and nearly spherical particles with irregularities on part or all of the spherical surface can also be used. Furthermore, as long as they are spherical, there are no particular limitations on whether they are entirely made of a single component, have an inner core and an outer shell made of different components such as a core-shell type, have different components dispersed inside, or are hollow powders with cavities inside.

When spherical powder is incorporated into a topical skin preparation, it is preferable that the total composition of the topical skin preparation contain 0.1 to 40% by mass, and particularly 0.5 to 30% by mass, of spherical powder. If the amount is less than 0.1% by mass, the effect of reducing spreadability may not be felt. If the amount is more than 40% by mass, the effect of further improving spreadability may not be observed, which is uneconomical.

Spherical silica is also called silicic anhydride or silicon dioxide, and preferably has an average particle size of 1 to 50 μm. Spherical silica may be porous, hollow, or non-porous. Commercially available products of such spherical silica include Godball E-6C, E-16C, D-11C, D-25C, D11-796C, E2-824C, Godball E-90C, ST Powder G-MG, ST Powder G-MY (all manufactured by Suzuki Oil Industries Co., Ltd.), Sunsphere NP-30, H-31, H-51, H-32, H-52, H-121, H-201 (manufactured by AGC Si-Tech Co., Ltd.), Silica Microbead P-500, P-4000 (all manufactured by JGC Catalysts and Chemicals Co., Ltd.), Silica Beads SB-150, SB-300, SB-700, SBNP-810 (all manufactured by Miyoshi Chemicals Co., Ltd.), etc.

The spherical calcium carbonate preferably has an average particle size of 1 to 50 μm. The spherical calcium carbonate used in the present invention may be a commercially available product, such as "Karumaru SCS-M5 (manufactured by Sakai Chemical Industry Co., Ltd.)."

The spherical barium sulfate preferably has an average particle size of 1 to 50 μm. The spherical barium sulfate used in the present invention may be a commercially available product, such as "Barimaru (manufactured by Sakai Chemical Industry Co., Ltd.)."

The spherical cellulose preferably has an average particle size of 1 to 50 μm. The spherical cellulose may be crystalline cellulose itself, or a cellulose derivative such as carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, or hydroxypropyl methyl cellulose, examples of which include "CELLULOBEADS D-10 (manufactured by Daito Kasei Co., Ltd.)" and "CELLULOBEADS USF (manufactured by Daito Kasei Co., Ltd.)."

The spherical starch preferably has an average particle size of 1 to 50 μm. The source of the starch is not particularly limited, but examples include corn, tapioca, rice, amaranth, wheat, potato, etc. It is preferable to use starch that has been subjected to a hydrophobic treatment.

Spherical modified starch is a general term for starches whose properties have been improved from those of natural starch by physical, chemical or enzymatic treatment of starch. Examples include hydroxypropyl starch, hydroxypropyl phosphate cross-linked starch, phosphate monoesterified phosphate cross-linked starch, phosphate cross-linked starch, sodium starch octenyl succinate, aluminum starch octenyl succinate, and calcium starch octenyl succinate, with aluminum starch octenyl succinate being preferred. It is preferable to use spherical modified starch that has been subjected to hydrophobic treatment.

Spherical silk is silk processed into a spherical shape, and preferably has an average particle size of 1 to 50 μm. It is preferable to use spherical silk that has been subjected to a hydrophobic treatment.

The spherical powder in the present invention may be surface-treated with a hydrophobic treatment agent. Examples of hydrophobic treatment include the following treatments, which may be used alone or in combination of two or more types, but are not limited thereto.
(1) Treatment using silicones such as methylhydrogenpolysiloxane (Silicon KF99P manufactured by Shin-Etsu Chemical Co., Ltd.), methylhydrogenpolysiloxane-dimethylpolysiloxane copolymer (Silicon KF-9901 manufactured by Shin-Etsu Chemical Co., Ltd.), dimethylpolysiloxane, branched silicone-based (ethoxy-functional) treatment agents described in JP-A 2001-72891 (product names: KF9908 and KF9909 manufactured by Shin-Etsu Chemical Co., Ltd.), and an acrylic silicone treatment agent described in WO2004/091563 (product name: KP574 manufactured by Shin-Etsu Chemical Co., Ltd.).
(2) Treatment using an alkylalkoxysilane compound such as octyltriethoxysilane (DYNASILAN OCTEO manufactured by EVONIK DEGUSSA), hexyltrimethoxysilane, or octadecyltriethoxysilane.
(3) Treatment with fatty acids such as palmitic acid and stearic acid.
(4) Treatment with alkylated sugars such as dextrin palmitate in which some of the hydroxyl groups of dextrin are alkyl esterified; metal soap treatment using an alkali metal salt or alkaline earth metal salt of a fatty acid, etc.
(5) Treatment with amino acids such as N-lauroyl-L-lysine, glutamic acid or its alkali salts, and acylated amino acids.
(6) Fluorine treatment using perfluoroalkyl phosphate diethanolamine salt, perfluoroalkyl phosphate, perfluorohexylethyltriethoxysilane, perfluorooctylethyltriethoxysilane, copolymers containing functional groups with perfluoroalkyl chain lengths of C4 to C6, or the like.
(7) Treatment with a quaternary ammonium salt such as distearyl dimethyl ammonium chloride.

The skin external preparation of the present invention contains (B) spherical glass beads (hereinafter sometimes simply referred to as glass beads) having an average particle size of 0.1 to 20 μm. The average particle size of the spherical glass beads is preferably 0.1 μm or more, more preferably 1 μm or more, even more preferably 5 μm or more, and even more preferably 7 μm or more. The average particle size of the spherical glass beads is preferably 20 μm or less, more preferably 15 μm or less, and even more preferably 13 μm or less. Furthermore, from the viewpoint of smoothness and cosmetic durability, the average particle size of the spherical glass beads is preferably 1 to 20 μm, more preferably 5 to 15 μm, and even more preferably 7 to 13 μm. The average particle size of the spherical glass beads can be measured as the number-average average particle size according to the principle of microscopy in accordance with the shape of the powder particles.
The spherical glass beads may be either hollow glass beads or solid glass beads, or may be used in combination, but preferably contain solid glass beads. When hollow glass beads are used, the glass beads may be broken during the steps of mixing, crushing, emulsification, etc. in the manufacturing process, and fragments of the glass beads may be mixed into the skin external preparation together with the hollow glass beads.
The spherical glass beads are indicated as cosmetic names (INCI names) such as borosilicate (Ca/Na; calcium sodium borosilicate) and borosilicate (Ca/Al; calcium aluminum borosilicate). In the present invention, glass of either name may be used, and it is more preferable to use borosilicate (Ca/Na).

The amount of the spherical glass beads is not particularly limited, but may be 1 to 30% by mass, preferably 1 to 20% by mass, based on the total amount of the topical skin preparation. For example, in a water- or oil-based topical skin preparation, the amount of the spherical glass beads is more preferably 1 to 10% by mass, based on the total amount of the topical skin preparation. In a powder or solid topical skin preparation, the amount of the spherical glass beads is more preferably 5 to 20% by mass, based on the total amount of the topical skin preparation.
The spherical glass beads may be used as they are, or may be subjected to a hydrophilic or hydrophobic treatment.

The skin external preparation of the present invention can be produced by a conventional production method.
The dosage form of the topical skin preparation of the present invention is not particularly limited, and dosage forms such as loose-type powdered topical skin preparation, solid oily topical skin preparation, paste-like oily topical skin preparation, liquid oily topical skin preparation, water-in-oil emulsion type topical skin preparation, oil-in-water emulsion type topical skin preparation, aqueous topical skin preparation, aerosol, etc. can be used.
The skin external preparation of the present invention may contain ingredients that can be generally contained in skin external preparations.

The present invention will be described in more detail below with reference to examples. However, the present invention is not limited to the following examples.

The present invention will be described in more detail below with reference to examples. However, the present invention is not limited to the following examples. The blend amounts are in mass % unless otherwise specified. The examples and comparative examples were prepared by standard methods.

The evaluation methods of the examples will be described.
[Dryness]
The inner part of the forearm was washed with a predetermined soap, and the moisture of the forearm was wiped off. Four areas of 3.0 cm x 3.0 cm were marked on each of the left and right forearms, and an appropriate amount of the Example or Comparative Example was applied using a puff, and the moisture content of the stratum corneum was measured immediately after application and 4 hours after application. The rate of change in moisture content immediately after application and 4 hours after application was calculated and evaluated according to the following criteria. The number of cases was 5, and the moisture content of the stratum corneum was measured using SKICON-200EX manufactured by IBS.
"◯": The example has a higher moisture content increase rate or a lower moisture content decrease rate.
"△": The examples and comparative examples are equivalent.
"X": The comparative example has a higher moisture content increase rate or a lower moisture content decrease rate.
[Makeup retention]
After 4 hours, the Example or Comparative Example remaining on the inside of the forearm was visually observed and compared.
"◯": The remaining amount is greater in the examples.
"△": The examples and comparative examples are equivalent.
"X": The comparative example has a larger remaining amount.

The glass beads used were "COVABEAD CRYSTAL" (manufactured by SENSIENT COSMETIC TECHNOLOGIES; average particle size 11 μm), which has the cosmetic name borosilicate (Ca/Na).

Claims (1)

A skin topical preparation containing (A) and (B) ( excluding skin topical preparations containing one or more types of powder selected from polymethyl methacrylate, methyl methacrylate crosspolymer, and nylon-12).
(A): One or more selected from boron nitride, barium sulfate , spherical silica, spherical calcium carbonate, spherical cellulose, spherical starch, spherical modified starch, and spherical silk; (B): Spherical glass beads having an average particle size of 0.1 to 20 μm.